Disease modification can be defined as treatments that affect the underlying pathophysiology of the disease and have a beneficial outcome. In the struggle to decrease the development of disease in many inflammatory conditions such as rheumatoid arthritis, psoriasis, and psoriatic arthritis, multiple sclerosis, and Crohn's disease, the disease-modifying agent class, including treatments such as anti-TNF agents and immunomodulators, averting the progression of each disease and also the market is experiencing notable growth. However, the landscape has changed with the entry of disease-modifying agents. Several new disease-modifying drugs are in the line, all of which will offer important options for patients with these diseases, thus promoting the growth of the disease-modifying agents market.
COVID-19 Impact analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the disease-modifying agents market.
Top Impacting Factors
- Increase in cases of inflammatory diseases, surge in geriatric population, rise in demand for minimally invasive procedure & advanced treatments such as disease modifying agents are the factors that drive the growth of the disease modifying agents market.
- Disease-modifying anti-rheumatic agents work to suppress the body's overactive immune and/or inflammatory systems; anti-TNFs are extremely effective treatments; disease-modifying agents are also effective for osteoarthritis; however, the agents are still under the clinical trial phase. Limited availability of products is anticipated to provide a lucrative opportunity to launch disease-modifying agents in the market.
- Few factors expected to hinder the growth of the disease modifying agents market include drug recalls by the FDA and EMA and increase in cost of multiple sclerosis disease-modifying agents.
Market Trends
Promising Product Pipeline Expected to Flourish the Market
Companies are taking efforts to develop therapeutic modalities for underlying pathophysiological changes in Alzheimer’s disease and other neurodegenerative disorders.
A phase 3 study of isradipine is being carried out as a disease-modifying agent in patients with early Parkinson's disease by STEADY-PD III, funded by National Institute of Neurological Disorders and Stroke (NINDS).
In September 2020, Prothena Corporation plc declared the results of the Phase 2 PASADENA study of prasinezumab, which is the first anti-inflammatory, anti-alpha-synuclein antibody to show efficacy in patients with early Parkinson's disease.
Key Benefits of the Report
- This study presents the analytical depiction of the disease-modifying agents industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the disease-modifying agents market share.
- The current market is quantitatively analyzed to highlight the disease-modifying agents market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed disease-modifying agents market analysis based on competitive intensity and how the competition will take shape in coming years
Questions answered in the disease-modifying agents Report
- Who are the leading players active in the gamete preservation market?
- What are the current trends that will influence the market in the next few years?
- What is "Disease-modifying agents "?
- What is "Disease-modifying agents" Market prediction in the future?
- Who are the leading global players in the "Disease-modifying agents" Market?
Disease-Modifying Agents Market, by Drug Class Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Indication |
|
 By Therapy Type |
|
 By Route of Administration |
|
 By Region |
|
 By End User |
|
 Key Market Players | Antares Pharma, Inc., Nordic Group Bv, Merck KGaA, Biogen Inc., Hospira, Inc., Pfizer Inc, Accord Healthcare Inc, Elan Pharma India Pvt Ltd., Fresenius Kabi, Teva Pharmaceutical Industries Ltd. |
Loading Table Of Content...
